Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

Summary

This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.

Timeline

Start

2026-10-31

Primary completion

2028-07-31

Completion

2030-07-31

Drugs

Indications